Tominersen

Update on huntingtin-lowering strategies under investigation for Huntington’s disease 4:14
Update on huntingtin-lowering strategies under investigation for Huntington’s disease
Ann Morgan et al. • 16 Sep 2022
The impact of wild-type HTT suppression on brain function 0:50
The impact of wild-type HTT suppression on brain function
Ann Morgan et al. • 16 Sep 2022
Huntingtin lowering: what level of wildtype protein knockdown is safe? 2:21
Huntingtin lowering: what level of wildtype protein knockdown is safe?
Michael Hayden • 27 Sep 2022
Moving forwards after disappointing data in the Huntington’s disease space 1:05
Moving forwards after disappointing data in the Huntington’s disease space
Patrick Weydt • 23 Sep 2022
Ongoing trials with importance for Huntington’s disease 4:24
Ongoing trials with importance for Huntington’s disease
Jee Bang • 4 Apr 2022
Huntingtin-lowering strategies for Huntington’s disease 2:56
Huntingtin-lowering strategies for Huntington’s disease
Anne Rosser • 18 Jun 2021
Treatment of neurodegenerative disorders at EAN 2021 2:08
Treatment of neurodegenerative disorders at EAN 2021
Tiago Outeiro • 18 Jun 2021
The latest clinical trials in Huntington’s disease: valbenazine, targeting behavior, and novel DMTs 4:28
The latest clinical trials in Huntington’s disease: valbenazine, targeting behavior, and novel DMTs
Tiago Mestre • 26 Apr 2021
ASO tominersen for Huntington’s disease in Phase III trials 2:20
ASO tominersen for Huntington’s disease in Phase III trials
Edward Wild • 4 Sep 2020
The content of VJNeurology is intended for healthcare professionals